scispace - formally typeset
S

Shyam Karki

Researcher at Bristol-Myers Squibb

Publications -  9
Citations -  255

Shyam Karki is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Dissolution testing & Microcrystalline cellulose. The author has an hindex of 5, co-authored 9 publications receiving 59 citations. Previous affiliations of Shyam Karki include Celgene.

Papers
More filters
Journal ArticleDOI

Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.

TL;DR: This review provides an updated overview of manufacturing techniques for preparing ASDs, and selection strategies are proposed to identify suitable manufacturing methods, which may aid in the development of ASDs with satisfactory physical stability.
Journal ArticleDOI

3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment.

TL;DR: The work illustrated the potential application of FDM technology in the development of oral fixed dose combination for personalized clinical treatment by minimizing the degradation of RFC in the acidic condition and potentially avoid drug-drug interaction.
Journal ArticleDOI

Decoding the small size challenges of mini-tablets for enhanced dose flexibility and micro-dosing.

TL;DR: In this article, a platform formulation with 60, 80, and 100 µm (particle size D6,3) ibuprofen at 3, 14, and 25% loadings were directly compressed into 1.2, 1.5, 2, and 2.5 µm diameter mini-tablets.
Journal ArticleDOI

Formulation and performance of Irbesartan nanocrystalline suspension and granulated or bead-layered dried powders - Part I.

TL;DR: Optized Irbesartan nanocrystalline suspension showed superior in vitro dissolution profile compared to unmilled suspension and remained crystalline post drying, and drug concentration and type of stabilizer were found to be significant in particle size reduction.
Journal ArticleDOI

Development of low dose micro-tablets by high shear wet granulation process.

TL;DR: This study provides a framework for developing low dose micro-tablets with acceptable quality attributes using HSWG process for micro-dosing, enhanced dose flexibility, and decreased excipient burden.